Programmed cell death-1 inhibitor combination treatment for recurrent proficient mismatch repair/miscrosatellite-stable type endometrial cancer:A case report

作     者：Chong-Ya Zhai Lu-Xi Yin Wei-Dong Han 

作者机构：Department of Medical OncologyXiasha CampusSir Run Run Shaw HospitalCollege of MedicineZhejiang UniversityHangzhou 310020Zhejiang ProvinceChina Department of Medical OncologySir Run Run Shaw HospitalCollege of MedicineZhejiang UniversityHangzhou 310020Zhejiang ProvinceChina 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2022年第10卷第21期

页      面：7474-7482页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by the Hangzhou Health and Family Planning and Science and Technology Program No.OO20190347 

主　　题：Refractory endometrial cancer Proficient mismatch repair Miscrosatellite-stable Immunotherapy Case report 

摘      要：BACKGROUND Endometrial cancer(EC)is one of the most common cancers of the female reproductive tract,and the incidence is increasing *** using programmed cell death-1(PD-1)inhibitors is an emerging research topic and treatment strategy for refractory gynecological ***,clinical management of EC with checkpoint inhibitors requires ***,we discuss a case of refractory proficient mismatch repair(pMMR)/miscrosatellitestable(MSS)EC treated with a combination of PD-1 and angiogenesis inhibitors and offer a review of the pathophysiology and clinical outcomes based on previous *** SUMMARY A 62-year-old woman diagnosed with invasive or metastatic EC in 2015 was treated with six courses of chemotherapy and refused further *** years later,she developed chest pain,and lung biopsy indicated thyroid transcription factor-1(-),Napsin A(-),estrogen receptor(+),progesterone receptor(+),anaplastic lymphoma kinase(D5F3)(-),and receptor tyrosine kinase(D4D6)(-)metastatic *** testing results showed low tumor mutation burden,pMMR,PD ligand 1(-),MSS,and HLA-class 1 heterogeneous *** patient was started on toripalimab combined with nab-paclitaxel for seven cycles(every 3 wk),but this regimen was terminated because of an intolerable chemotherapy adverse *** disease progressed in 2020,and the patient’s treatment was switched from nab-paclitaxel to anlotinib,while immunotherapy using toripalimab was *** patient achieved a major partial response with well-tolerated toxicities,and treatment is *** Molecular testing is advised for clinical classifications of EC owing to its high *** this case,the patient had pMMR/MSS EC and achieved a positive outcome with combination PD-1 inhibitor *** results warrant further clinical exploration.